Related references
Note: Only part of the references are listed.Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials
Alexander Drilon et al.
LANCET ONCOLOGY (2020)
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials
Robert C. Doebele et al.
LANCET ONCOLOGY (2020)
Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001
A. T. Shaw et al.
ANNALS OF ONCOLOGY (2019)
Development of Simplified in Vitro P-Glycoprotein Substrate Assay and in Silico Prediction Models To Evaluate Transport Potential of P-Glycoprotein
Rikiya Ohashi et al.
MOLECULAR PHARMACEUTICS (2019)
Challenges of developing small-molecule kinase inhibitors for brain tumors and the need for emphasis on free drug levels
Timothy P. Heffron
NEURO-ONCOLOGY (2018)
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
A. Drilon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Somatic chromosomal engineering identifies BCAN-NTRK1 as a potent glioma driver and therapeutic target
Peter J. Cook et al.
NATURE COMMUNICATIONS (2017)
Crizotinib resistance: implications for therapeutic strategies
I. Dagogo-Jack et al.
ANNALS OF ONCOLOGY (2016)
Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor
Maria Menichincheri et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
Elena Ardini et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Impact of Membrane Drug Transporters on Resistance to Small-Molecule Tyrosine Kinase Inhibitors
Claudia Neul et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2016)
Label-free assay for the assessment of nonspecific binding of positron emission tomography tracer candidates
Frauke Assmus et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2015)
Estimation of Drug Binding to Brain Tissue: Methodology and in Vivo Application of a Distribution Assay in Brain Polar Lipids
Sara Belli et al.
MOLECULAR PHARMACEUTICS (2015)
Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The landscape of kinase fusions in cancer
Nicolas Stransky et al.
NATURE COMMUNICATIONS (2014)
Calibration of In Vitro Multidrug Resistance Protein 1 Substrate and Inhibition Assays as a Basis to Support the Prediction of Clinically Relevant Interactions In Vivo
Agnes Poirier et al.
DRUG METABOLISM AND DISPOSITION (2014)
CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib
Daniel B. Costa et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Validation of 96-well Equilibrium Dialysis with Non-radiolabeled Drug for Definitive Measurement of Protein Binding and Application to Clinical Development of Highly-Bound Drugs
Maciej J. Zamek-Gliszczynski et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2011)
Long-term survival in patients with non-small cell lung cancer and synchronous brain metastasis treated with whole-brain radiotherapy and thoracic chemoradiation
Oscar Arrieta et al.
RADIATION ONCOLOGY (2011)
Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding
MJ Banker et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2003)
Share Paper
